CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW

CERO THERAPEUTICS HOLDINGS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.01+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $253.05K
P/E (TTM): –
Dividend yield: 172833.33%

CERO THERAPEUTICS HOLDINGS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Research & Development	–	5.29	–
General & Administrative	–	2.39	2.84
Operating Expenses	–	7.68	2.91
Operating Income	–	-7.68	-2.91
Interest Expense	–	-0.14	–
Interest & Investment Income	–	0.49	2.84
Other Non-Operating Income	–	0.39	–
Legal Settlements	–	0.01	–
Pretax Income	-20	-2.44	-0.07
Income Tax Expense	–	0.09	0.60
Net Income incl. Noncontrolling Interests	20	–	–
Net Income	-20	-7.29	-0.67
Net Income to Common	–	-7.29	–
EPS (Basic)(per share)	–	-24,972.80	–
EPS (Diluted)(per share)	–	-24,972.80	–
Shares Outstanding (Basic, Weighted)(shares)	–	0.00	–
Shares Outstanding (Diluted, Weighted)(shares)	–	0.00	–
Dividend per Share(per share)	10.37	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 542.7%

Financial strength

Current ratio: 0.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: 172833.33%